Opinion
Video
Author(s):
Panelists discuss the evolving management of RSV, highlighting the importance of increasing awareness and education, anticipating advances in testing, data reporting, and treatment options like monoclonal antibodies and antivirals, and considering future vaccination strategies such as booster doses to enhance prevention and patient outcomes.
The management of RSV is expected to evolve significantly in the coming years, with ongoing efforts to increase awareness and education among both health care providers and patients. A key focus will be helping people understand what RSV is, how vaccination works, and the benefits and risks involved. This foundational knowledge is essential as more individuals become eligible for vaccines and other preventative measures, ensuring informed decision-making and greater acceptance of new treatments.
Advancements in testing and data reporting for RSV are anticipated to improve, similar to the systems established for influenza and COVID-19. These improvements will allow for better tracking of the virus’s spread and impact. Additionally, development of monoclonal antibodies and antiviral medications is expected to expand, offering new options to reduce the severity of RSV infections. Researchers also hope to gain a deeper understanding of why some patients experience more severe disease, which could lead to more targeted and effective treatments in the future.
Looking ahead, there may be changes in vaccination strategies, including the potential introduction of booster or repeat doses. Currently, only 1 RSV vaccine dose is recommended, but as more data emerges over time, recommendations may evolve to include additional doses to maintain immunity. This ongoing research and adjustment will be critical in refining RSV prevention and management, ultimately improving patient outcomes and reducing the burden of this respiratory virus.
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.